JP2010508855A - 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用 - Google Patents

前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用 Download PDF

Info

Publication number
JP2010508855A
JP2010508855A JP2009536481A JP2009536481A JP2010508855A JP 2010508855 A JP2010508855 A JP 2010508855A JP 2009536481 A JP2009536481 A JP 2009536481A JP 2009536481 A JP2009536481 A JP 2009536481A JP 2010508855 A JP2010508855 A JP 2010508855A
Authority
JP
Japan
Prior art keywords
spink1
overexpression
erg
rna
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009536481A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010508855A5 (enExample
Inventor
アルル エム． チャナイヤン
スコット エイ． トムリンス
ダニエル アール． ローデス
ロヒト メーラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan-Ann Arbor
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Publication of JP2010508855A publication Critical patent/JP2010508855A/ja
Publication of JP2010508855A5 publication Critical patent/JP2010508855A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8135—Kazal type inhibitors, e.g. pancreatic secretory inhibitor or ovomucoid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2009536481A 2006-11-08 2007-11-08 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用 Pending JP2010508855A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85775806P 2006-11-08 2006-11-08
US90687607P 2007-03-14 2007-03-14
PCT/US2007/084090 WO2008058239A2 (en) 2006-11-08 2007-11-08 Spink1 as a prostate cancer marker and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013218134A Division JP5850898B2 (ja) 2006-11-08 2013-10-21 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用

Publications (2)

Publication Number Publication Date
JP2010508855A true JP2010508855A (ja) 2010-03-25
JP2010508855A5 JP2010508855A5 (enExample) 2011-01-27

Family

ID=39365376

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009536481A Pending JP2010508855A (ja) 2006-11-08 2007-11-08 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用
JP2013218134A Expired - Fee Related JP5850898B2 (ja) 2006-11-08 2013-10-21 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013218134A Expired - Fee Related JP5850898B2 (ja) 2006-11-08 2013-10-21 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用

Country Status (8)

Country Link
US (1) US20100129804A1 (enExample)
EP (1) EP2079851B1 (enExample)
JP (2) JP2010508855A (enExample)
CN (2) CN103233063A (enExample)
AU (1) AU2007317306B2 (enExample)
CA (1) CA2668961A1 (enExample)
IL (2) IL198526A (enExample)
WO (1) WO2008058239A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013524783A (ja) * 2010-04-02 2013-06-20 ベリデックス・エルエルシー 限局性前立腺癌患者に対するｐｓａ再発の遺伝子に基づく予測
WO2023276768A1 (ja) * 2021-06-29 2023-01-05 国立大学法人京都大学 低酸素バイオマーカー及びその利用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206697A1 (en) * 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Spink1 targeted therapy
US20140308657A1 (en) * 2010-12-09 2014-10-16 Philadelphia Health & Education Corporation D/B/A Drexel University College Of Medicine Serine protease inhibitor kazal antibodies
EP3348652B1 (en) * 2011-05-12 2023-07-26 MDxHealth Research B.V. Molecular markers in prostate cancer
EP3492606B1 (en) * 2011-08-22 2023-10-04 Exosome Diagnostics, Inc. Urine biomarkers
WO2013036755A1 (en) * 2011-09-09 2013-03-14 Sloan-Kettering Institute For Cancer Research Etv1 antibodies and uses thereof
US20130143237A1 (en) * 2011-11-29 2013-06-06 Genentech, Inc. Compositions and methods for prostate cancer analysis
CN103436594A (zh) * 2012-10-16 2013-12-11 科蒂亚(新乡)生物技术有限公司 一种bdna在尿液中检测pca3的应用
CN102968558B (zh) * 2012-11-14 2015-11-18 叶定伟 一种预测初诊前列腺癌骨转移风险的装置
KR20170116009A (ko) * 2014-12-01 2017-10-18 프라운호퍼-게젤샤프트 추어 푀르더룽 데어 안게반텐 포르슝 에.파우. 전립선암의 진단을 위한 신규한 rna-바이오마커 시그니처
CN104531878B (zh) * 2015-01-04 2017-11-10 上海市同济医院 一种联合lncRNA和AR3检测试剂盒及应用
CN105717082A (zh) * 2016-02-02 2016-06-29 管晓翔 一种用于检测三阴性乳腺癌瘤内异质性的方法
KR101948385B1 (ko) * 2016-09-01 2019-05-13 충북대학교 산학협력단 전립선암 예후 분석용 신규 바이오마커 및 그의 용도
CN109521457B (zh) * 2018-09-25 2022-10-21 中国辐射防护研究院 一种基于信息准则的γ辐射源项划分方法及系统
CN111110849B (zh) * 2018-10-11 2021-09-10 中国科学院上海营养与健康研究所 丝氨酸蛋白酶抑制因子Kazal 1型在制备细胞衰老及肿瘤诊断或调控制剂中的应用
CN109678950B (zh) * 2019-01-08 2022-05-10 灏灵赛奥（天津）生物科技有限公司 spink1抗原、能够特异性结合spink1的抗体及其功能片段及其应用和产品
CN109776679B (zh) * 2019-01-08 2022-06-17 灏灵赛奥（天津）生物科技有限公司 一种丝氨酸蛋白酶抑制因子spink1的抗体、其制备方法和应用
US12319967B2 (en) 2019-08-21 2025-06-03 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
US11788091B2 (en) 2019-08-21 2023-10-17 University Of Virginia Patent Foundation Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
CN111308095A (zh) * 2020-03-04 2020-06-19 北京师范大学 用于诊断前列腺癌的尿液蛋白标记物
EP4232605A4 (en) * 2020-11-11 2024-09-25 University of Virginia Patent Foundation METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NON-CODING RNA OVERLAPPING THE LCK GENE REGULATING PROSTATE CANCER CELL GROWTH
CN115181801B (zh) * 2022-07-11 2026-03-31 中山大学附属第一医院 Bhlhe22在前列腺癌骨转移免疫治疗中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028655A2 (en) * 2004-08-13 2006-03-16 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4323546A (en) * 1978-05-22 1982-04-06 Nuc Med Inc. Method and composition for cancer detection in humans
JP3448090B2 (ja) * 1994-02-16 2003-09-16 浜松ホトニクス株式会社 エネルギー移動検出法およびその装置
US20050214309A1 (en) * 1994-03-18 2005-09-29 Hinrichs Steven H Methods and compositions for modulating transcription factor activity
US5854206A (en) * 1995-08-25 1998-12-29 Corixa Corporation Compounds and methods for treatment and diagnosis of prostate cancer
CO4600637A1 (es) * 1996-03-15 1998-05-08 Corixa Corp Compuestos para inmunoterapia e inmunodiagnosis del cancer de prostata
US20030185830A1 (en) * 1997-02-25 2003-10-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1005546A2 (en) * 1997-02-25 2000-06-07 Corixa Corporation Compounds for immunotherapy of prostate cancer and methods for their use
AU7019498A (en) * 1997-04-10 1998-10-30 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US6828429B1 (en) * 1999-03-26 2004-12-07 Henry M. Jackson Foundation For The Advancement Of Military Medicine Prostate-specific gene, PCGEM1, and the methods of using PCGEM1 to detect, treat, and prevent prostate cancer
WO2002024680A1 (en) * 2000-09-21 2002-03-28 Smithkline Beecham P.L.C. Imidazole derivatives as raf kinase inhibitors
US6897024B2 (en) * 2001-05-31 2005-05-24 Stichting Katholieke Universiteit More Particularly The University Medical Centre Nijmegen Nucleic acid molecules comprising the promoter for PCA3, and uses thereof
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7217807B2 (en) * 2002-11-26 2007-05-15 Rosetta Genomics Ltd Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
DE602004024549D1 (de) * 2003-09-05 2010-01-21 Univ Jefferson Diagnose und überwachung von hepatozellulärem karzinom
US20060275794A1 (en) * 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
CA2622295C (en) * 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
AU2007324128B2 (en) * 2006-10-10 2013-10-10 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in ERG gene expression and detection and treatment methods based on those alterations
US20100305188A1 (en) * 2007-10-03 2010-12-02 Kyowa Hakko Kirin Co., Ltd. Nucleic acid capable of regulating the proliferation of cell

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028655A2 (en) * 2004-08-13 2006-03-16 Millennium Pharmaceuticals, Inc. Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JPN6012058558; Ｅｕｒ．Ｕｒｏｌ．Ｓｕｐｐｌ．，Ｖｏｌ．５，Ｎｏ．１４（Ｓｅｐｔ．２００６）ｐ．７９１（１７-１８） *
JPN6012058560; Ｐｒｏｃ．Ａｍｅｒ．Ａｓｓｏｃ．Ｃａｎｃｅｒ　Ｒｅｓ．，Ｖｏｌ．４７（Ａｐｒ．２００６）ｐ．８２３（Ａｂｓｔ．＃３５０７） *
JPN6012058561; Ｃａｎｃｅｒ　Ｌｅｔｔ．，Ｖｏｌ．２３７（Ｊｕｎ．２００６）ｐ．２９８-３０４ *
JPN6012058563; Ｓｃｉｅｎｃｅ，Ｖｏｌ．３１０（２００５）ｐ．６４４-６４８ *
JPN6012058565; Ｅｕｒ．Ｕｒｏｌ．Ｓｕｐｐｌ．，Ｖｏｌ．５，Ｎｏ．２（Ａｐｒ．２００６）ｐ．２７５（１０１２） *
JPN6012058567; Ｃａｎｃｅｒ　Ｃｅｌｌ，Ｖｏｌ．８（２００５）ｐ．３９３-４０６ *
JPN6012058569; Ｐｒｏｓｔａｔｅ，Ｖｏｌ．６１（２００４）ｐ．２０９-２１４ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013524783A (ja) * 2010-04-02 2013-06-20 ベリデックス・エルエルシー 限局性前立腺癌患者に対するｐｓａ再発の遺伝子に基づく予測
WO2023276768A1 (ja) * 2021-06-29 2023-01-05 国立大学法人京都大学 低酸素バイオマーカー及びその利用

Also Published As

Publication number Publication date
IL198526A0 (en) 2010-02-17
EP2079851A4 (en) 2010-09-01
JP5850898B2 (ja) 2016-02-03
CA2668961A1 (en) 2008-05-15
EP2079851A2 (en) 2009-07-22
IL215373A0 (en) 2011-11-30
CN103233063A (zh) 2013-08-07
IL198526A (en) 2012-10-31
WO2008058239A3 (en) 2008-11-06
IL215373A (en) 2013-07-31
WO2008058239A2 (en) 2008-05-15
EP2079851B1 (en) 2015-01-07
CN101652484A (zh) 2010-02-17
CN101652484B (zh) 2013-03-20
WO2008058239A9 (en) 2009-12-23
US20100129804A1 (en) 2010-05-27
AU2007317306B2 (en) 2012-06-14
JP2014087335A (ja) 2014-05-15
AU2007317306A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
JP5850898B2 (ja) 前立腺癌マーカーとしてのｓｐｉｎｋ１およびその使用
EP3018216B1 (en) Recurrent gene fusions in prostate cancer
US10190173B2 (en) Recurrent gene fusions in prostate cancer
JP5800817B2 (ja) 前立腺癌における再発性遺伝子融合
ES2700877T3 (es) Fosfodiesterasa 4D7 como marcador de cáncer de próstata
US11015224B2 (en) RAF gene fusions
US7713693B1 (en) Human cancer cell specific gene transcript
CN113846165A (zh) 生物标志物在预测结直肠癌对奥沙利铂治疗敏感性中的应用
KR101007576B1 (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커
KR101065027B1 (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커
KR20100018026A (ko) 대장암 과발현 유전자를 이용한 대장암 진단 마커

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130523

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130619